Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Beam Therapeutics(BEAM) Zacks Investment Research·2024-05-08 15:56Beam Therapeutics Inc. (BEAM) incurred a loss of $1.21 per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.45. The company had recorded a loss of $1.33 per share in the year-ago quarter.Total revenues, comprising license and collaboration revenues, came in at $7.4 million in the first quarter compared with $24.2 million in the year-ago period. The top line missed the Zacks Consensus Estimate of $14 million.Quarter in DetailResearch and development expenses amou ...